---
title: "CTMX: Varseta-M advances in CRC and GI cancers, supported by strong cash and expanded Regeneron collaboration"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295154296.md"
description: "Varseta-M's development in CRC and other GI cancers advanced with strong clinical and operational progress, while financials reflect a robust cash position and increased R&D investment. Key milestones include a major Regeneron collaboration expansion and new executive hires.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-06T23:08:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295154296.md)
  - [en](https://longbridge.com/en/news/295154296.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295154296.md)
---

# CTMX: Varseta-M advances in CRC and GI cancers, supported by strong cash and expanded Regeneron collaboration

Varseta-M's development in CRC and other GI cancers advanced with strong clinical and operational progress, while financials reflect a robust cash position and increased R&D investment. Key milestones include a major Regeneron collaboration expansion and new executive hires.

Based on

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [CTMX.US](https://longbridge.com/en/quote/CTMX.US.md)
- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)

## Related News & Research

- [NewEdge Advisors LLC Has $5.88 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN](https://longbridge.com/en/news/295508474.md)
- [12:37 ETREGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit](https://longbridge.com/en/news/294851069.md)
- [GRAL: Significant growth, clinical validation, and regulatory milestones position the test for broader adoption](https://longbridge.com/en/news/295557836.md)
- [Purple Biotech presents new preclinical IM1240 cancer data at EACR 2026 congress](https://longbridge.com/en/news/295224384.md)
- [Biovica signs lab services agreement with leading US cancer center for DiviTum TKa testing](https://longbridge.com/en/news/295067317.md)